Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in Novo’s weight-loss ...
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...
Eli Lilly has reduced the price of its weight-loss drug Zepbound, offering higher doses in vials at a discount to boost demand and compete with Novo Nordisk's Wegovy. The price adjustment aims to ease ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...